Polymorphism -765G>C in cyclooxygenase-2 and risk of colorectal cancer

Laboratory Medicine

Volumn 44, Issue 2, 2013, Pages

  Khorshidi, Fatemeh ^a   Mohebbi, Seyed Reza ^a   Haghighi, Mahdi Montazer ^a   Taleghani, Mohammad Yaghoob ^a   Azimzadeh, Pedram ^a   Golmohammadi, Mina ^a   Alidadi, Maede ^a   Romani, Sara ^a   Vahedi, Mohsen ^a   Mojarad, Ehsan Nazemalhosseini ^a   Zali, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer (CRC); Cyclooxygenase 2 (COX 2); Polymerase chain reaction (PCR); Restriction fragment length polymorphism; RFLP; Rs20417; Single nucleotide polymorphism (SNP)

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; BINDING SITE; CANCER LOCALIZATION; CANCER RISK; CASE CONTROL STUDY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROMOTER REGION; PROTEIN EXPRESSION; RECTUM CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84881172868     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMVAX2QHHIBWY1H7     Document Type: Article

References (44)

1. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med. 2002;137:603-612.
2. Brown JR, Dubois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840-2855.
3. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Internat. 2012.
4. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101-2114.
5. Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol. 2005;56:57-73.
6. Greenhough A, Smartt H J M, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30:377-386.
7. Pereira C, Sousa H, Ferreira P, et al. -765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol. 2006;12:5473-5478.
8. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S. Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem. 2003;253:141-149.
9. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest. 2001;107:1491-1495.
10. Cao Y, Pearman AT, Zimmerman GA, Mcintyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Nat Acad Sci U S A. 2000;97:11280-11285.
11. Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J. 1994;302:723-727.
12. Bertino JR, Dannenberg AJ, Dubois RN, eds. COX-2: A New Target for Cancer Prevention and Treatment. Vol. 37. Basel: S Karger Ag; 2003.
13. Langsenlehner U, Yazdani-Biuki B, Eder T, et al. The cyclooxygenase-2 (PTGS2) 8473T> C polymorphism is associated with breast cancer risk. Clin Canc Res. 2006;12:1392-1394.
14. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25:229-235.
15. Sakoda LC, Gao Y-T, Chen BE, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis. 2006;27:1251-1256.
16. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3' UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer. 2005;48:11-17.
17. Gallicchio L, McSorley MA, Newschaffer CJ, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106:1443-1452.
18. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T> C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer. 2006;6:70.
19. Cox DG, Pontes C, Guino E, et al, for the Bellvitge Colorectal Cancer Study Group. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Brit J Cancer. 2004;91:339-343.
20. Sørensen M, Autrup H, Tjønneland A, Overvad K, Raaschou-Nielsen O. A genetic polymorphism in prostaglandin synthase 2 (8473, T>C) and the risk of lung cancer. Cancer Letters. 2005;226:49-54.
21. Shahedi K, Lindström S, Zheng S, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119:668-672.
22. Liu F, Pan K, Zhang X, et al. Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology. 2006;130:1975-1984.
23. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005;129:565-576.
24. Zhang XM, Miao X P, Tan W, et al. Genetic polymorphisms in the promoter region of cyclooxygenase-2 and their association with risk of gastric cancer [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006;28:119-123.
25. Panguluri R C K, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004;25:961-966.
26. Koh W-P, Yuan J-M, Van Den Berg D, Lee H-P, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Brit J Cancer. 2004;90:1760-1764.
27. Hamajima N, Takezaki T, Matsuo K, et al. Genotype frequencies of cyclooxygenease 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac J Cancer Prev. 2001;2:57-62.
28. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004;25:2467-2472.
29. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews Cancer. 2006;6:130-140.
30. Tazawa R, Xu XM, Wu KK, Wang LH. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun. 1994;203:190-199.
31. Pereira C, Pimentel-Nunes P, Brandão C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol. 2010;22:607-613.
32. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer. 2002;31:147-154.
33. Sansbury LB, Millikan RC, Schroeder JC, et al. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control. 2006;17:257-266.
34. Tan W, Wu J, Zhang X, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007;28:1197-1201.
35. Hoff JH, Te Morsche R H M, Roelofs H M J, Van Der Logt E M J, Nagengast FM, Peters W H M. COX-2 polymorphisms -765G->C and - 1 1 9 5 A - > G and colorectal cancer risk. World J Gastroenterol. 2009;15:4561-4565.
36. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression. Arterioscler Thromb Vasc Biol. 2002;22:1631-1636.
37. Mahdavinia M, Bishehsari F, Ansari R, et al. Family history of colorectal cancer in Iran. BMC Cancer. 2005;5:112.
38. Pahlavan PS, Kanthan R. The epidemiology and clinical findings of colorectal cancer in Iran. J Gastrointest Liver Dis. 2006;15:15-19.
39. Daraei A, Salehi R, Mohamadhashem F. PTGS2 (COX2)-765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep. 2012;39:5219-5224.
40. Biramijamal F, Basatvat S, Hossein-Nezhad A, et al. Association of COX-2 promoter polymorphism with gastrointestinal tract cancer in Iran. Biochem Genet. 2010;48:915-923.
41. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, González-Aguilera JJ, Fernández-Peralta AM. Effect of COX2-765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes and Control. 2009;20:1421-1429.
42. Thompson CL, Plummer SJ, Merkulova A, et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol. 2009;15:2240-2244.
43. Ulrich CM, Whitton J, Yu J-H, et al. PTGS2 (COX-2)-765G >C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev. 2005;14:616-619.
44. Siemes C, Visser LE, Coebergh J W W, Hofman A, Uitterlinden AG, Stricker B H C. Protective effect of NSAIDs on cancer and influence of COX-2 C G genotype. Curr Cancer Drug Targets. 2008;8:75.